Tailored antisense oligonucleotides for ultrarare CNS diseases: an experience-based best practice framework for individual patient evaluation
Individualized mutation-specific RNA therapies offer promise, in particular, for individuals with ultrarare neurological diseases that affect only few families or even single patients worldwide. Outside traditional drug development pathways, however, clinicians and scientists face the challenge of s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
9 September 2025
|
| In: |
Molecular therapy. Nucleic Acids
Year: 2025, Volume: 36, Issue: 3, Pages: 1-13 |
| ISSN: | 2162-2531 |
| DOI: | 10.1016/j.omtn.2025.102615 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.omtn.2025.102615 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2162253125001696 
|
| Author Notes: | Rebecca Schüle, Holm Graessner, Annemieke Aartsma-Rus, Willeke M.C. van Roon-Mom, N=1 Collaborative (N1C), 1 Mutation 1 Medicine Consortium (1M1M), and Matthis Synofzik |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1949664511 | ||
| 003 | DE-627 | ||
| 005 | 20260120100500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260120s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.omtn.2025.102615 |2 doi | |
| 035 | |a (DE-627)1949664511 | ||
| 035 | |a (DE-599)KXP1949664511 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schüle-Freyer, Rebecca |d 1975- |e VerfasserIn |0 (DE-588)137544472 |0 (DE-627)695848283 |0 (DE-576)30411118X |4 aut | |
| 245 | 1 | 0 | |a Tailored antisense oligonucleotides for ultrarare CNS diseases |b an experience-based best practice framework for individual patient evaluation |c Rebecca Schüle, Holm Graessner, Annemieke Aartsma-Rus, Willeke M.C. van Roon-Mom, N=1 Collaborative (N1C), 1 Mutation 1 Medicine Consortium (1M1M), and Matthis Synofzik |
| 264 | 1 | |c 9 September 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 1. Juli 2025, Artikelversion: 18. Juli 2025 | ||
| 500 | |a Gesehen am 20.01.2026 | ||
| 520 | |a Individualized mutation-specific RNA therapies offer promise, in particular, for individuals with ultrarare neurological diseases that affect only few families or even single patients worldwide. Outside traditional drug development pathways, however, clinicians and scientists face the challenge of systematically evaluating whether individual patients with severe ultrarare diseases might be eligible for and potentially benefit from such approaches. This complex evaluation involves biological, clinical, psychological, and ethical aspects. Based on the experience of the 1 Mutation 1 Medicine (1M1M) consortium, we here propose a best practice framework that enables the systematic evaluation of individual patients for tailored genomic therapies, using transparent criteria to comprehensively assess each individual’s benefit-risk balance. By example of individually tailored antisense oligonucleotide approaches in neurology, this framework takes into account characteristics of the (1) underlying variant, (2) underlying disease, and (3) individual patient. It thereby allows a systematic, balanced, fact-based evaluation that appreciates the full complexity and preferences of each individual patient, performed by a multi-stakeholder treatment board. This operational framework will thus pave the way for systematic, rational patient-centric evaluation and decision-making in the rapidly evolving field of individualized “n-of-1” precision genomic medicine in clinical neurology. | ||
| 650 | 4 | |a antisense oligonucleotides | |
| 650 | 4 | |a best practice framework | |
| 650 | 4 | |a decision-making | |
| 650 | 4 | |a individualized tailored therapy | |
| 650 | 4 | |a MT: Oligonucleotides: Therapies and Applications | |
| 650 | 4 | |a n-of-1 therapy | |
| 650 | 4 | |a patient assessment | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a RNA therapy | |
| 650 | 4 | |a therapy evaluation | |
| 700 | 1 | |a Graessner, Holm |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aartsma-Rus, Annemieke |e VerfasserIn |4 aut | |
| 700 | 1 | |a van Roon-Mom, Willeke M. C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Synofzik, Matthis |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy. Nucleic Acids |d New York, NY : Nature Publ. Group, 2012 |g 36(2025), 3 vom: Sept., Artikel-ID 102615, Seite 1-13 |h Online-Ressource |w (DE-627)718632702 |w (DE-600)2662631-7 |w (DE-576)365782785 |x 2162-2531 |7 nnas |a Tailored antisense oligonucleotides for ultrarare CNS diseases an experience-based best practice framework for individual patient evaluation |
| 773 | 1 | 8 | |g volume:36 |g year:2025 |g number:3 |g month:09 |g elocationid:102615 |g pages:1-13 |g extent:13 |a Tailored antisense oligonucleotides for ultrarare CNS diseases an experience-based best practice framework for individual patient evaluation |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.omtn.2025.102615 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2162253125001696 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260120 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 137544472 |a Schüle-Freyer, Rebecca |m 137544472:Schüle-Freyer, Rebecca |d 910000 |d 911100 |e 910000PS137544472 |e 911100PS137544472 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1949664511 |e 4855038725 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Rebecca Schüle, Holm Graessner, Annemieke Aartsma-Rus, Willeke M.C. van Roon-Mom, N=1 Collaborative (N1C), 1 Mutation 1 Medicine Consortium (1M1M), and Matthis Synofzik"]},"language":["eng"],"recId":"1949664511","person":[{"display":"Schüle-Freyer, Rebecca","given":"Rebecca","role":"aut","family":"Schüle-Freyer"},{"family":"Graessner","role":"aut","given":"Holm","display":"Graessner, Holm"},{"family":"Aartsma-Rus","role":"aut","given":"Annemieke","display":"Aartsma-Rus, Annemieke"},{"display":"van Roon-Mom, Willeke M. C.","given":"Willeke M. C.","family":"van Roon-Mom","role":"aut"},{"given":"Matthis","display":"Synofzik, Matthis","family":"Synofzik","role":"aut"}],"note":["Online verfügbar: 1. Juli 2025, Artikelversion: 18. Juli 2025","Gesehen am 20.01.2026"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Tailored antisense oligonucleotides for ultrarare CNS diseases","title":"Tailored antisense oligonucleotides for ultrarare CNS diseases","subtitle":"an experience-based best practice framework for individual patient evaluation"}],"physDesc":[{"extent":"13 S.","noteIll":"Illustrationen"}],"id":{"doi":["10.1016/j.omtn.2025.102615"],"eki":["1949664511"]},"relHost":[{"name":{"displayForm":["American Society of Gene & Cell Therapy"]},"recId":"718632702","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["718632702"],"issn":["2162-2531"],"zdb":["2662631-7"]},"title":[{"title":"Molecular therapy","title_sort":"Molecular therapy","partname":"Nucleic Acids"}],"origin":[{"dateIssuedKey":"2012","publisherPlace":"New York, NY","publisher":"Nature Publ. Group","dateIssuedDisp":"2012-"}],"part":{"text":"36(2025), 3 vom: Sept., Artikel-ID 102615, Seite 1-13","issue":"3","pages":"1-13","extent":"13","volume":"36","year":"2025"},"language":["eng"],"pubHistory":["1.2012 -"],"note":["Gesehen am 19. Januar 2017"],"disp":"Tailored antisense oligonucleotides for ultrarare CNS diseases an experience-based best practice framework for individual patient evaluationMolecular therapy. Nucleic Acids","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Molecular Therapy / Nucleic Acids"}]}],"origin":[{"dateIssuedDisp":"9 September 2025","dateIssuedKey":"2025"}]} | ||
| SRT | |a SCHUELEFRETAILOREDAN9202 | ||